Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
04 05 2021
Historique:
entrez: 5 5 2021
pubmed: 6 5 2021
medline: 14 10 2021
Statut: epublish

Résumé

Herpesvirus entry and spread requires fusion of viral and host cell membranes, which is mediated by the conserved surface glycoprotein B (gB). Upon activation, gB undergoes a major conformational change and transits from a metastable prefusion to a stable postfusion conformation. Although gB is a structural homolog of low-pH-triggered class III fusogens, its fusion activity depends strictly on the presence of the conserved regulatory gH/gL complex and nonconserved receptor binding proteins, which ensure that fusion occurs at the right time and space. How gB maintains its prefusion conformation and how gB fusogenicity is controlled remain poorly understood. Here, we report the isolation and characterization of a naturally selected pseudorabies virus (PrV) gB able to mediate efficient gH/gL-independent virus-cell and cell-cell fusion. We found that the control exerted on gB by the accompanying viral proteins is mediated via its cytosolic domain (CTD). Whereas gB variants lacking the CTD are inactive, a single mutation of a conserved asparagine residue in an alpha-helical motif of the ectodomain recently shown to be at the core of the gB prefusion trimer compensated for CTD absence and uncoupled gB from regulatory viral proteins, resulting in a hyperfusion phenotype. This phenotype was transferred to gB homologs from different alphaherpesvirus genera. Overall, our data propose a model in which the central helix acts as a molecular switch for the gB pre-to-postfusion transition by conveying the structural status of the endo- to the ectodomain, thereby governing their cross talk for fusion activation, providing a new paradigm for herpesvirus fusion regulation.

Identifiants

pubmed: 33947756
pii: mBio.00557-21
doi: 10.1128/mBio.00557-21
pmc: PMC8262866
pii:
doi:

Substances chimiques

Amino Acids 0
Viral Envelope Proteins 0
glycoprotein B, Simplexvirus 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 Vallbracht et al.

Références

J Virol. 2010 May;84(10):4923-35
pubmed: 20200237
J Virol. 2002 Sep;76(18):9271-83
pubmed: 12186911
J Virol. 2014 Nov;88(21):12193-201
pubmed: 25142593
J Virol. 1997 Jan;71(1):17-24
pubmed: 8985318
J Virol. 2001 Dec;75(23):11526-33
pubmed: 11689634
PLoS Pathog. 2017 Dec 20;13(12):e1006777
pubmed: 29261802
J Virol. 2010 Dec;84(23):12292-9
pubmed: 20861251
J Virol. 2000 Aug;74(15):7137-45
pubmed: 10888654
Curr Protoc Bioinformatics. 2006 Oct;Chapter 5:Unit-5.6
pubmed: 18428767
J Virol. 2017 Dec 14;92(1):
pubmed: 29046441
J Virol. 2017 Apr 13;91(9):
pubmed: 28228592
PLoS Pathog. 2018 Dec 3;14(12):e1007452
pubmed: 30507948
Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):4176-81
pubmed: 27035968
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):866-71
pubmed: 20080767
J Virol. 2009 May;83(9):4520-7
pubmed: 19244335
PLoS Pathog. 2013;9(12):e1003806
pubmed: 24367260
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Virol. 2003 May;77(9):5339-51
pubmed: 12692236
Virology. 1959 Apr;7(4):394-407
pubmed: 13669311
J Virol. 1999 Apr;73(4):3014-22
pubmed: 10074151
Methods Mol Biol. 2005;292:187-96
pubmed: 15507709
J Gen Virol. 2014 Apr;95(Pt 4):948-959
pubmed: 24431235
Virology. 1996 Aug 1;222(1):262-8
pubmed: 8806507
J Virol. 1995 Aug;69(8):4758-68
pubmed: 7609042
J Virol. 2002 Jan;76(2):591-9
pubmed: 11752150
Adv Exp Med Biol. 2011;714:91-101
pubmed: 21506008
J Virol. 2019 Mar 21;93(7):
pubmed: 30700600
J Gen Virol. 1996 Sep;77 ( Pt 9):2221-9
pubmed: 8811022
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2880-5
pubmed: 19196955
Adv Virus Res. 2019;104:225-281
pubmed: 31439150
J Virol. 2000 Aug;74(15):6760-8
pubmed: 10888614
J Virol. 2008 Jul;82(13):6299-309
pubmed: 18417564
mBio. 2018 Oct 16;9(5):
pubmed: 30327436
J Virol. 2012 Aug;86(15):8171-84
pubmed: 22623783
Sci Adv. 2020 Sep 25;6(39):
pubmed: 32978151
Viruses. 2012 May;4(5):800-32
pubmed: 22754650
Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17474-9
pubmed: 15583133
Cell. 2008 Mar 21;132(6):935-44
pubmed: 18358807
J Virol. 2015 Dec;89(24):12262-72
pubmed: 26401042
J Virol. 2003 Oct;77(19):10179-85
pubmed: 12970403
J Virol. 2001 Nov;75(21):10054-64
pubmed: 11581374
Nat Commun. 2020 Aug 18;11(1):4141
pubmed: 32811830
Nucleic Acids Res. 2015 Jul 1;43(W1):W389-94
pubmed: 25883141
Bio Protoc. 2017 Mar 05;7(5):e2162
pubmed: 34458475
Viruses. 2015 Dec 11;7(12):6552-69
pubmed: 26690469
J Gen Virol. 2001 Jan;82(Pt 1):215-226
pubmed: 11125174
Nature. 2010 Oct 14;467(7317):859-62
pubmed: 20944748
J Virol. 2002 May;76(9):4390-400
pubmed: 11932406
J Virol. 2010 Dec;84(24):12924-33
pubmed: 20943984
Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):E3901-10
pubmed: 26157134
J Virol. 2015 Dec 09;90(5):2264-72
pubmed: 26656712
J Virol. 2003 Jun;77(12):6731-42
pubmed: 12767993
Virology. 2015 May;479-480:498-507
pubmed: 25866377
Avian Dis. 2010 Mar;54(1 Suppl):622-6
pubmed: 20521704
J Mol Biol. 2013 Jun 12;425(11):2056-2071
pubmed: 23500487
J Virol. 2005 Sep;79(18):11588-97
pubmed: 16140736
J Virol. 2013 Sep;87(18):10139-47
pubmed: 23843635
Curr Opin Virol. 2013 Feb;3(1):13-9
pubmed: 23107819
Nat Struct Mol Biol. 2018 May;25(5):416-424
pubmed: 29728654
Science. 2006 Jul 14;313(5784):217-20
pubmed: 16840698
J Virol. 1992 Feb;66(2):831-9
pubmed: 1309917
Adv Exp Med Biol. 2013;790:178-95
pubmed: 23884592

Auteurs

Melina Vallbracht (M)

Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany Melina.Vallbracht@fli.de ThomasC.Mettenleiter@fli.de.

Henriette Lötzsch (H)

Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.

Barbara G Klupp (BG)

Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.

Walter Fuchs (W)

Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.

Benjamin Vollmer (B)

Centre for Structural Systems Biology, Heinrich-Pette-Institut, Leibniz-Institut für Experimentelle Virologie, Hamburg, Germany.

Kay Grünewald (K)

Centre for Structural Systems Biology, Heinrich-Pette-Institut, Leibniz-Institut für Experimentelle Virologie, Hamburg, Germany.

Marija Backovic (M)

Institut Pasteur, Structural Virology Unit, Department of Virology, CNRS UMR3569, Paris, France.

Felix A Rey (FA)

Institut Pasteur, Structural Virology Unit, Department of Virology, CNRS UMR3569, Paris, France.

Thomas C Mettenleiter (TC)

Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany Melina.Vallbracht@fli.de ThomasC.Mettenleiter@fli.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH